Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
AUTOR(ES)
Lim, Ee Tuan
FONTE
BioMed Central
RESUMO
S100B belongs to a family of calcium-binding proteins implicated in intracellular and extracellular regulatory activities. This study of serum S100B in primary progressive multiple sclerosis (PPMS) is based on data obtained from a randomized, controlled trial of Interferon β-1a in subjects with PPMS. The key questions were whether S100B levels were associated with either disability or MRI findings in primary progressive MS and whether Interferon β-1a has an effect on their S100B levels. Serial serum S100B levels were measured using an ELISA method. The results demonstrated that serum S100B is not related to either disease progression or MRI findings in subjects with primary progressive MS given Interferon β-1a. Furthermore there is no correlation between S100B levels and the primary and secondary outcome measures.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=524502Documentos Relacionados
- A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis.
- Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
- Serum S100B Levels in Patients with Lupus Erythematosus: Preliminary Observation
- Serum and cerebrospinal fluid S100B concentrations in patients with neurocysticercosis
- Association of S100B polymorphisms and serum S100B with risk of systemic lupus erythematous in a Chinese population
